Tvardi Therapeutics, Inc. (NASDAQ:TVRD – Get Free Report) was the recipient of a large growth in short interest in the month of October. As of October 15th, there was short interest totaling 375,939 shares, a growth of 67.5% from the September 30th total of 224,403 shares. Based on an average daily volume of 168,469 shares, the short-interest ratio is currently 2.2 days. Approximately 3.0% of the shares of the company are sold short.
Institutional Investors Weigh In On Tvardi Therapeutics
A number of institutional investors and hedge funds have recently bought and sold shares of the business. GSA Capital Partners LLP bought a new position in shares of Tvardi Therapeutics in the second quarter worth about $34,000. Susquehanna International Group LLP bought a new stake in Tvardi Therapeutics during the 2nd quarter valued at approximately $63,000. Finally, BlackRock Inc. bought a new stake in Tvardi Therapeutics during the 2nd quarter valued at approximately $181,000. 44.66% of the stock is owned by institutional investors.
Analysts Set New Price Targets
Several analysts recently issued reports on TVRD shares. Chardan Capital assumed coverage on shares of Tvardi Therapeutics in a research report on Tuesday, October 20th. They set a “buy” rating for the company. Raymond James Financial upgraded shares of Tvardi Therapeutics from a “market perform” rating to an “outperform” rating and set a $10.00 price target on the stock in a research report on Wednesday, July 8th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Tvardi Therapeutics in a research note on Friday, October 2nd. UBS Group raised shares of Tvardi Therapeutics to an “outperform” rating and set a $10.00 price objective for the company in a research report on Wednesday, July 8th. Finally, Piper Sandler raised shares of Tvardi Therapeutics from a “neutral” rating to an “overweight” rating and set a $13.00 price objective for the company in a research report on Wednesday, July 8th. One analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Tvardi Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus price target of $9.40.
Check Out Our Latest Stock Analysis on TVRD
Tvardi Therapeutics Trading Up 1.6%
TVRD opened at $0.81 on Tuesday. The company has a 50 day simple moving average of $1.36 and a two-hundred day simple moving average of $2.75. Tvardi Therapeutics has a 1-year low of $0.77 and a 1-year high of $5.69.
Tvardi Therapeutics (NASDAQ:TVRD – Get Free Report) last announced its quarterly earnings data on Friday, August 14th. The company reported ($0.69) EPS for the quarter, missing the consensus estimate of ($0.65) by ($0.04). On average, equities research analysts expect that Tvardi Therapeutics will post -2.23 EPS for the current year.
Tvardi Therapeutics Company Profile
Tvardi Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing therapies for cancer and other serious diseases involving abnormal STAT3 signaling. STAT3 is a protein that can contribute to tumor growth, treatment resistance and immune suppression, making it a potential target for drug development.
The company’s lead investigational product is TTI-101, an orally administered small-molecule inhibitor designed to block STAT3 activity. Tvardi is evaluating TTI-101 in clinical studies for solid tumors, including hepatocellular carcinoma and other advanced cancers.
Featured Articles
- Five stocks we like better than Tvardi Therapeutics
- Check Point’s Turnaround Could Be Closer Than Investors Think
- SpaceX Sent Verizon and T-Mobile Stocks Tumbling—Did Wall Street Overreact?
- SpaceX Starlink’s Telecom Ground Game Takes Shape
- AST SpaceMobile’s Brazil Breakthrough Could Set the Stage for a Q3 Stock Rebound
Receive News & Ratings for Tvardi Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tvardi Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
